Pfizer reported Q3 FY 2016 earnings of $0.61 per share (versus $0.60 in Q3 FY 2015), missing analysts' consensus estimate of $0.62.

The company's quarterly revenues amounted to $13.045 bln (+7.9% y/y), generally matching analysts' consensus estimate of $13.028 bln.

The company also issued updated guidance for FY 2016, projecting EPS of $2.38-2.43 versus analysts' consensus estimate of $2.47 (previously $2.38-2.48) and revenues of $52.0-53.0 bln versus analysts' consensus estimate of$53.15 bln (previously $51.0-53.0 bln).

PFE fell to $$30.83 (-2.78%) in pre-market trading.